Triptorelin
Also known as: Decapeptyl, GnRH Agonist, Triptorelin Pamoate, Trelstar
Triptorelin is a synthetic GnRH agonist that initially stimulates then suppresses LH and FSH production, leading to decreased testosterone levels in males and estrogen suppression in females.
Triptorelin is a 1311.45 g/mol research peptide. Triptorelin is a synthetic GnRH agonist that initially stimulates then suppresses LH and FSH production, leading to decreased testosterone levels in males and estrogen suppression in females.
Also called: Decapeptyl, GnRH Agonist, Triptorelin Pamoate
1311.45 g/mol
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
3.75-7.5
Typical Dose
mg
Overview
Triptorelin functions as a potent gonadotropin-releasing hormone (GnRH) agonist used primarily in research applications involving hormonal suppression. This synthetic decapeptide mimics natural GnRH but provides sustained receptor activation that paradoxically leads to desensitization and downregulation of pituitary gonadotroph cells. After an initial flare effect where LH and FSH levels spike, continued administration results in profound suppression of these hormones, effectively creating a chemical castration state. Research applications include studying hormonal feedback loops, investigating reproductive disorders, and examining the effects of androgen deprivation. The peptide's ability to create reversible hypogonadism makes it valuable for researchers studying hormone-dependent processes and recovery mechanisms.
Key Takeaways: Triptorelin
- Strongest evidence supports Triptorelin for testosterone suppression and lh and fsh suppression
- Research doses typically range from 3.75 to 7.5 mg via intramuscular
- 4 benefits with strong evidence, 2 moderate, 0 preliminary
- Half-life: 2.8-4 hours (immediate release), 3-4 weeks (depot formulations)
- 4 cited research studies in this guide
Mechanism of Action
Triptorelin binds to GnRH receptors on anterior pituitary gonadotroph cells with high affinity. Initial binding causes rapid release of stored LH and FSH, creating a temporary surge in gonadotropins. However, continuous receptor occupancy leads to desensitization and internalization of GnRH receptors. This downregulation prevents further gonadotropin synthesis and release, resulting in suppressed LH and FSH levels within 2-4 weeks. The subsequent reduction in gonadal stimulation dramatically decreases testosterone production in males and estrogen/progesterone in females, creating a reversible hypogonadal state that persists throughout treatment duration.
Research Benefits
Triptorelin at a Glance
Triptorelin binds to GnRH receptors on anterior pituitary gonadotroph cells with high affinity.
Testosterone Suppression
Strong EvidenceCreates profound suppression of testosterone to castrate levels (typically <50 ng/dL) within 2-4 weeks through GnRH receptor desensitization
LH and FSH Suppression
Strong EvidenceReduces luteinizing hormone and follicle-stimulating hormone to near-undetectable levels, enabling research into hypogonadal states
Reversible Hypogonadism Model
Strong EvidenceProvides a reliable method to study reversible androgen deprivation, with hormone levels recovering within 3-6 months after cessation
Estrogen Suppression in Females
Strong EvidenceSignificantly reduces estradiol levels in female research models, useful for studying estrogen-dependent processes
HPTA Recovery Research
Moderate EvidenceEnables investigation of hypothalamic-pituitary-testicular axis recovery patterns and optimization strategies
Hormonal Feedback Loop Studies
Moderate EvidenceAllows researchers to examine complex interactions between hypothalamic, pituitary, and gonadal hormones
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Testosterone suppression research | 3.75–7.5 mg | intramuscular |
| Acute hormonal response studies | 0.1–0.5 mg | subcutaneous |
| Female hormone suppression | 3.75–11.25 mg | intramuscular |
Frequency
Single injection for depot formulations, or daily for immediate-release forms
Timing
Any time of day for depot; consistent timing for daily administration
Cycle Length
1-6 months depending on research protocol
Research Notes
- 1Depot formulations provide sustained release for 1-3 months
- 2Initial testosterone flare may last 7-10 days before suppression occurs
- 3Higher doses do not provide additional suppression beyond maximum effect
- 4Recovery time varies but typically requires 3-6 months after cessation
Reconstitution Guide
Standard Reconstitution
Vial Size
3.75 mg
Bacteriostatic Water
2 mL
Concentration
19 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Triptorelin vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 24-36 months unopened, use immediately after reconstitution.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
24-36 months unopened, use immediately after reconstitution
Important Notes
- •Most commonly available as pre-formulated depot suspension
- •Lyophilized powder forms require gentle mixing to avoid foaming
- •Do not shake vigorously as this may damage the peptide structure
- •Single-use vials should not be stored after opening
Triptorelin Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Triptorelin Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Hot flashes and sweating
- !Decreased libido and sexual function
- !Fatigue and weakness
- !Mood changes and depression
- !Bone density reduction with prolonged use
- !Muscle mass decrease
- !Injection site reactions
- !Initial testosterone flare symptoms
- !Sleep disturbances
- !Cognitive changes
Potential Interactions
- ⚡May enhance effects of other hormone-suppressing compounds
- ⚡Potential interactions with testosterone replacement therapies
- ⚡May affect metabolism of drugs dependent on hepatic enzymes
- ⚡Can interact with medications affecting bone metabolism
- ⚡May influence insulin sensitivity and glucose metabolism
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Pharmacokinetics and pharmacodynamics of triptorelin pamoate in healthy male volunteers
Study demonstrated sustained testosterone suppression for 84 days following single 11.25mg injection, with complete recovery by 6 months
Long-term effects of GnRH agonist treatment on bone mineral density in men
Research showed significant bone density reduction during treatment but reversible changes upon discontinuation
Comparative study of different GnRH agonist formulations for testosterone suppression
Triptorelin achieved castrate testosterone levels in 95% of subjects within 4 weeks with sustained suppression
Recovery of reproductive function after GnRH agonist treatment cessation
Most subjects recovered normal testosterone levels within 3-6 months, with fertility parameters normalizing by 12 months
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Depot formulations typically suppress testosterone to castrate levels for 1-3 months depending on dose. The 3.75mg dose lasts about 4 weeks, while 11.25mg can maintain suppression for 12 weeks.
The first 7-10 days after injection cause a temporary surge in testosterone and LH levels before suppression occurs. This flare effect is due to initial receptor stimulation before desensitization.
Most research indicates testosterone levels begin recovering within 4-8 weeks after the last dose, with normal levels typically restored within 3-6 months. Full recovery may take up to 12 months in some cases.
Triptorelin is sometimes researched as a PCT option due to its ability to reset the HPTA, but it causes profound suppression first and requires careful timing and dosing protocols.
Common effects include hot flashes, decreased libido, fatigue, mood changes, and reduced muscle mass. Long-term use can affect bone density, so duration should be limited in research settings.
Triptorelin has similar efficacy to other GnRH agonists like leuprolide but may have slightly different pharmacokinetic profiles and injection frequencies depending on the formulation used.
Research doses typically range from 3.75mg to 11.25mg for depot formulations, administered intramuscularly every 4-12 weeks depending on the study protocol and desired suppression duration.
Yes, triptorelin suppresses the entire gonadal axis, reducing LH, FSH, estrogen, and progesterone in addition to testosterone. It may also affect growth hormone and insulin-like growth factor-1 levels.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.